Update in treatment of psoriatic arthritis

Psoriatic arthritis is a chronic rheumatic disease making part of spondylarthropathies. It is the most frequent chronic inflammatory rheumatism after rheumatoid arthritis. Eventhough, it is usually a benign affection, it may be destructive leading to handicap. Several new medications have been intro...

Full description

Saved in:

Bibliographic Details
Published in:	Tunisie Medicale Vol. 86; no. 12; p. 1036
Main Authors:	Abdelmoula, Leila Cheikhrouhou, Ben M'Barek, Rim, Yahia, Chiraz Ben Hadj, Tekaya, Raoudha, Testouri, Nadia, Chaabouni, Lilia, Zouari, Rafik
Format:	Journal Article
Language:	French
Published:	Tunisia 01-12-2008
Subjects:	Adalimumab Antibodies, Monoclonal - therapeutic use Antibodies, Monoclonal, Humanized Antirheumatic Agents - therapeutic use Arthritis, Psoriatic - drug therapy Dermatologic Agents - therapeutic use Humans Isoxazoles - therapeutic use Recombinant Fusion Proteins - therapeutic use Tumor Necrosis Factor-alpha - antagonists & inhibitors
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Psoriatic arthritis is a chronic rheumatic disease making part of spondylarthropathies. It is the most frequent chronic inflammatory rheumatism after rheumatoid arthritis. Eventhough, it is usually a benign affection, it may be destructive leading to handicap. Several new medications have been introduced, including anti-tumor necrosis factor (TNF alpha blockers) and leflunomide for treatment of psoriatic arthritis. Many studies show the efficacy of these medications in this disease.
ISSN:	0041-4131